Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches.

Leukemia - 1 Dec 2017

Pearson S, Williamson A J K, Blance R, Somervaille T C P, Taylor S, Azadbakht N, Whetton A D, Pierce A

Abstract excerpt

In excess of 90% of patients with polycythaemia vera (PV) express a mutated form of Janus kinase 2 (JAK2), JAK2V617F. Such aberrant proteins offer great potential for the treatment of these diseases; however, inhibitors to JAK2 have had limited success in the clinic in terms of curing the disease. To understand the effects of this oncogene in haematopoietic cells with the aim of improving treatment strategies, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Janus Kinase 2
Share to Polycythemia Vera

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Interaction Mapping

Share to Protein Interaction Maps

Share to Proteome

Share to Proteomics

Share to Proto-Oncogene Proteins c-myc

Share to Transforming Growth Factor beta

Source

Open in PubMed Open full text

Identifiers

PMID: 28533538
DOI: 10.1038/leu.2017.143
PMCID: PMC5729335

Genes

MYC
JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches.PMID 28533538Read ↗

A proteomic study of myeloproliferative neoplasms using reverse-phase protein arrays.Semantic proximity Read ↗

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.Semantic proximity Read ↗

Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.Semantic proximity Read ↗

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera–like diseaseSemantic proximity Read ↗

Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms.Semantic proximity Read ↗

JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.Semantic proximity Read ↗

Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.Semantic proximity Read ↗

Differential biological activity of disease-associated JAK2 mutants.Semantic proximity Read ↗

Identification of an acquired JAK2 mutation in polycythemia vera.Semantic proximity Read ↗

Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients.Semantic proximity Read ↗

Characterization of Glycoproteoforms of Integrins α2 and β1 in Megakaryocytes in the Occurrence of JAK2V617F Mutation-Induced Primary Myelofibrosis.Semantic proximity Read ↗

Proteomic study of the impact of the JAK2-V617F mutation on the phenotype of essential thrombocythemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.